Autolus Therapeutics (NASDAQ:AUTL) Trading 13.3% Higher Following Strong Earnings

Key Points

• Autolus Therapeutics shares rose 13.3% after the company reported quarterly EPS of negative $0.15, beating expectations by $0.06, while revenue of $45.69 million exceeded estimates of $38.56 million.
• Analyst sentiment is broadly positive, with the stock holding a consensus “Moderate Buy” rating and an average price target of $8.75, substantially above its recent trading price near $2.35.
• Institutional investors own 72.83% of the company, while Autolus continues developing CAR-T cancer therapies including AUTO1 for acute lymphoblastic leukemia and AUTO3 for diffuse large B-cell lymphoma.

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Get Free Report) was up 13.3% during mid-day trading on Tuesday after the company announced better than expected quarterly earnings. The company traded as high as $2.3590 and last traded at $2.3450. Approximately 982,049 shares traded hands during trading, a decline of 42% from the average session volume of 1,687,173 shares. The stock had previously closed at $2.07.

The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.06. Autolus Therapeutics had a negative net margin of 311.98% and a negative return on equity of 128.59%. The company had revenue of $45.69 million during the quarter, compared to analyst estimates of $38.56 million.

Wall Street Analyst Weigh In

AUTL has been the subject of several research analyst reports. Jefferies Financial Group upgraded shares of Autolus Therapeutics to a "strong-buy" rating in a research note on Monday, April 20th. HC Wainwright reiterated a "buy" rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a research note on Monday, August 3rd. Weiss Ratings lowered Autolus Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a report on Friday, July 31st. Finally, Wall Street Zen raised Autolus Therapeutics from a "strong sell" rating to a "sell" rating in a research report on Saturday. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $8.75.

Hedge Funds Weigh In On Autolus Therapeutics

Several hedge funds have recently bought and sold shares of AUTL. Alphabet Inc. bought a new position in shares of Autolus Therapeutics in the second quarter worth $1,117,000. Syncona Portfolio Ltd bought a new position in Autolus Therapeutics in the 2nd quarter worth about $26,625,152,000. Hennion & Walsh Asset Management Inc. raised its holdings in shares of Autolus Therapeutics by 2.5% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 451,403 shares of the company's stock valued at $722,000 after acquiring an additional 11,197 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of Autolus Therapeutics by 115.6% in the 2nd quarter. GAMMA Investing LLC now owns 15,499 shares of the company's stock valued at $25,000 after acquiring an additional 8,309 shares in the last quarter. Finally, Waverly Advisors LLC purchased a new stake in shares of Autolus Therapeutics in the 1st quarter valued at about $37,000. Hedge funds and other institutional investors own 72.83% of the company's stock.

Autolus Therapeutics Stock Performance

The stock has a market cap of $614.03 million, a P/E ratio of -2.12 and a beta of 2.07. The stock has a 50-day moving average price of $1.59 and a 200-day moving average price of $1.55.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company's leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source